IP Library › Granted Patent US 12,012,444
Granted Patent B2
US 12,012,444 · App. 18/116,166 · Granted Jun 18, 2024

Anti-VEGF protein compositions and methods for producing the same

Inventors: Shunhai Wang (Scarsdale, NY); Ning Li (Greenwich, CT); Hunter Chen (New York, NY); Amardeep Singh Bhupender Bhalla (Montvale, NJ); Shawn M. Lawrence (Nyack, NY); Amy S. Johnson (Briarcliff Manor, NY); Meghan Casey (Ringwood, NJ); Jaimie Grapel (Waldwick, NJ)
Assignee: Regeneron Pharmaceuticals, Inc.
C07K14/71A61K38/1866C07K1/06C07K1/113C07K1/18C07K1/22C07K1/36C07K16/22C07K16/283C12N5/0018C12N5/0031C12N15/66C12P21/02C12P21/06G01N30/80C07K2317/622C07K2319/30C07K2319/33C12N2800/10G01N2030/027
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,012,444
App. No.
18/116,166
Granted
Jun 18, 2024
Kind
B2
Abstract

The present disclosure pertains to compositions comprising anti-VEGF proteins.

Claims (19)

1. A culture media composition comprising chemically defined media (CDM) and aflibercept, wherein said aflibercept includes about 0.02% to about 1% oxidized aflibercept and wherein said oxidized aflibercept is oxidized at one or more amino acid residues selected from the group consisting of tryptophan, histidine and a combination thereof.

2. The culture media composition of claim 1 , wherein said aflibercept includes between about 0.02% and about 0.5% oxidized aflibercept.

3. The culture media composition of claim 1 , wherein said oxidized aflibercept includes His19 residue oxidation.

4. The culture media composition of claim 3 , wherein a relative abundance of the oxidized His19 residue is at least about 0.02%.

5. The culture media composition of claim 1 , wherein said oxidized aflibercept includes His86 residue oxidation.

6. The culture media composition of claim 5 , wherein a relative abundance of the oxidized His86 residue is at least about 0.02%.

7. The culture media composition of claim 1 , wherein said oxidized aflibercept includes His95 residue oxidation.

8. The culture media composition of claim 7 , wherein a relative abundance of the oxidized His95 residue is at least about 0.03%.

9. The culture media composition of claim 1 , wherein said oxidized aflibercept includes His110 residue oxidation.

10. The culture media composition of claim 9 , wherein a relative abundance of the oxidized His110 residue is at least about 0.04%.

11. The culture media composition of claim 1 , wherein said oxidized aflibercept includes His145 residue oxidation.

12. The culture media composition of claim 11 , wherein a relative abundance of the oxidized His145 residue is at least about 0.19%.

13. The culture media composition of claim 1 , wherein said oxidized aflibercept includes His203 residue oxidation.

14. The culture media composition of claim 1 , wherein said oxidized aflibercept includes His209 residue oxidation.

15. The culture media composition of claim 14 , wherein a relative abundance of the oxidized His209 residue is at least about 0.11%.

16. The culture media composition of claim 1 , wherein said oxidized aflibercept includes Trp58 residue oxidation.

17. The culture media composition of claim 16 , wherein a relative abundance of the oxidized Trp58 residue is at least about 0.03%.

18. The culture media composition of claim 1 , wherein said oxidized aflibercept includes Trp138 residue oxidation.

19. The culture media composition of claim 18 , wherein a relative abundance of the oxidized Trp138 residue is at least about 0.02%.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2023
From: WANG, SHUNHAI; LI, NING; CHEN, HUNTER; BHUPENDER BHALLA, AMARDEEP SINGH; LAWRENCE, SHAWN M.; JOHNSON, AMY S.; CASEY, MEGHAN E.; GRAPEL, JAIMIE
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 065549/0917 →
Continuity (7)
Continuation 17858724 · Jul 6, 2022
Continuation 17575425 · Jan 13, 2022
Division 17460578 · Aug 30, 2021
Continuation 16996293 · Aug 18, 2020
Provisional Application 63065012 · Aug 13, 2020
Provisional Application 62944635 · Dec 6, 2019
Related Publication 20230235019A1 · Jul 27, 2023
Cited By (1)
US 12,319,728